British crew member among those evacuated from MV Hondius, which is heading for Canary Islands after Spain said vessel could dock Europe live – latest updates What is hantavirus? Three people with suspected hantavirus, including a British crew member, have been medically evacuated from the cruise ship linked to the outbreak. The crew member, along with a Dutch colleague and another passenger, were...
British crew member among those evacuated from MV Hondius, which is heading for Canary Islands after Spain said vessel could dock Europe live – latest updates What is hantavirus? Three people with suspected hantavirus, including a British crew member, have been medically evacuated from the cruise ship linked to the outbreak. The crew member, along with a Dutch colleague and another passenger, were taken from the Dutch-flagged cruise ship MV Hondius for onward travel to the Netherlands, the World Health Organization (WHO) confirmed. Continue reading...
Battered school indoor shoes, reportedly worn by graduating schoolgirls, have appeared in online shops in Japan, sparking fierce criticism over the fetishisation of young women. Removing outdoor shoes before entering homes, schools, companies and other public buildings is a deeply rooted custom in the country, tied to cleanliness and respect for shared spaces. Known as uwabaki, Japan’s traditional...
Battered school indoor shoes, reportedly worn by graduating schoolgirls, have appeared in online shops in Japan, sparking fierce criticism over the fetishisation of young women. Removing outdoor shoes before entering homes, schools, companies and other public buildings is a deeply rooted custom in the country, tied to cleanliness and respect for shared spaces. Known as uwabaki, Japan’s traditional indoor shoes are typically white and shaped like ballet flats. At schools, from kindergarten...
In a rare interview, the director has said he wants to do justice to Homer’s ‘the original non-linear narrative’. How will that translate on screen? • New trailer for Nolan’s The Odyssey released online The excitement around Christopher Nolan’s forthcoming film of the Odyssey has been taken up a notch this week with the launch of a new trailer and the director appearing on Stephen Colbert’s US cha...
In a rare interview, the director has said he wants to do justice to Homer’s ‘the original non-linear narrative’. How will that translate on screen? • New trailer for Nolan’s The Odyssey released online The excitement around Christopher Nolan’s forthcoming film of the Odyssey has been taken up a notch this week with the launch of a new trailer and the director appearing on Stephen Colbert’s US chatshow to give a rare interview. With fresh information emerging about the film, which is scheduled to be released on 17 July, it’s worth taking stock of what we know about Nolan’s adaptation of Homer’s ancient Greek epic, starring Matt Damon as Odysseus. And how faithful to the original poem is it likely to be? Continue reading...
zetter/iStock via Getty Images Australia will commit A$10 billion ($7.22 billion) to expand domestic fuel stockpiles and create a permanent, government-owned reserve, Prime Minister Anthony Albanese said Wednesday, in a move aimed at strengthening the country’s energy resilience. The plan would lift onshore fuel holdings to roughly 1 billion litres (264 million gallons), enough to cover at least 5...
zetter/iStock via Getty Images Australia will commit A$10 billion ($7.22 billion) to expand domestic fuel stockpiles and create a permanent, government-owned reserve, Prime Minister Anthony Albanese said Wednesday, in a move aimed at strengthening the country’s energy resilience. The plan would lift onshore fuel holdings to roughly 1 billion litres (264 million gallons), enough to cover at least 50 days of demand. Officials say the expanded reserves are designed to protect the country from supply disruptions, particularly after recent shortages linked to tensions in the Middle East. Australia currently imports about 80% of its fuel and maintains around 30 days of supply, largely held by private companies under regulatory requirements. Albanese said the initiative will be included in next week’s federal budget as part of a broader fuel security and resilience package. Of the total funding, A$3.2 billion will be directed toward establishing and maintaining the strategic reserve, with a focus on diesel and aviation fuel capacity. The government said the reserve would be used to address shortages affecting critical users, particularly in regional areas, during future disruptions. The policy also raises the minimum stockholding requirement for fuel importers and refiners by 10 days, at an estimated cost of A$34.7 million. A further A$7.5 billion will support fuel and fertiliser supply chains through a mix of loans, equity investments, guarantees, insurance and pricing mechanisms intended to encourage storage and availability. Energy Minister Chris Bowen noted that Australia has been an outlier among International Energy Agency members in lacking a government-controlled reserve. More on Crude Oil Futures, Brent Futures U.S. February Oil Production Rebounds Commodities: Trump's 'Project Freedom' Pause Weighs On Oil Prices Gas Prices Surge To Highest Level Since July 2022 Oil prices fall after reports that U.S. is nearing framework deal to halt Iran war U.S.-Iran reportedly...
(RTTNews) - AMETEK, Inc. (AME), a provider of industrial technology solutions, announced Wednesday that it has agreed to acquire a portfolio of instrumentation businesses from Indicor, LLC in an all-cash deal at approximately $5.0 billion.
(RTTNews) - AMETEK, Inc. (AME), a provider of industrial technology solutions, announced Wednesday that it has agreed to acquire a portfolio of instrumentation businesses from Indicor, LLC in an all-cash deal at approximately $5.0 billion.
watch now VIDEO 6:20 06:20 How Barrière is betting on vitamin patches to shake up the supplement industry Retail The supplement industry has seen booming demand over the past few years as consumers increasingly focus on health and wellness. Along with that, wearable patches have become more mainstream, with brands like The What Supp Co and The Good Patch marketing products that they say deliver th...
watch now VIDEO 6:20 06:20 How Barrière is betting on vitamin patches to shake up the supplement industry Retail The supplement industry has seen booming demand over the past few years as consumers increasingly focus on health and wellness. Along with that, wearable patches have become more mainstream, with brands like The What Supp Co and The Good Patch marketing products that they say deliver the same results as oral vitamins without having to swallow pills. One company, Barrière, says it's bringing something new to the table. It currently has an offering of patches that offer consumers help on everything ranging from sleep to energy boosts to immune support. CEO and co-founder Cleo Davis-Urman told CNBC exclusively that the company is projecting to double its 2025 revenue to reach $10 million in 2026, with a current valuation of $19 million. Davis-Urman also told CNBC that Barrière is also launching into 1,700 Walmart stores with its two newest offerings, including a motion sickness patch and what the company said is the first-ever lactose intolerance patch on the market. Barrière has grown from having a presence in just over 600 stores in the second quarter of 2025 to being available in more than 6,000 stores in the second quarter of 2026, according to the company. Its products are sold in major retailers including Target , Ulta and Urban Outfitters . Barrière vitamin patches packaging. CNBC Yet even as wearable patches become more available, the market remains largely unregulated by the Food and Drug Administration in the United States. Barrière's products are not FDA-approved. The agency oversees supplements according to the Dietary Supplement Health and Education Act of 1994, which classifies the products as food rather than as drugs and largely allows the marketing to be left up to the companies. Davis-Urman said Barrière chose to manufacture its products in the U.K., where the FDA-equivalent agency upholds the "strictest regulations possible." "Transparency...
Insulet press release ( PODD ): Q1 Non-GAAP EPS of $1.42 beats by $0.23 . Revenue of $761.7M (+33.9% Y/Y) beats by $31.6M . 2026 Outlook: For the quarter ending June 30, 2026 and year ending December 31, 2026, the Company is providing the following guidance (revenue in constant currency): Q2 2026 Guidance FY 2026 Guidance (as of 5/6/2026) FY 2026 Prior Guidance (as of 2/18/2026) U.S. Omnipod 18% -...
Insulet press release ( PODD ): Q1 Non-GAAP EPS of $1.42 beats by $0.23 . Revenue of $761.7M (+33.9% Y/Y) beats by $31.6M . 2026 Outlook: For the quarter ending June 30, 2026 and year ending December 31, 2026, the Company is providing the following guidance (revenue in constant currency): Q2 2026 Guidance FY 2026 Guidance (as of 5/6/2026) FY 2026 Prior Guidance (as of 2/18/2026) U.S. Omnipod 18% - 20% 20% - 22% 20% - 22% International Omnipod 28% - 30% 26% - 28% 24% - 26% Total Omnipod 21% - 23% 22% - 24% 21% - 23% Drug Delivery ~(50)% ~(50)% ~(50)% Total 20% - 22% 21% - 23% 20% - 22% Adjusted Operating Margin 1 ~100 bps YoY expansion ~100 bps YoY expansion Adjusted EPS Growth 1 >25% >25% Click to enlarge More on Insulet Insulet Corporation (PODD) Discusses Omnipod 5 Manufacturing Issue and Medical Device Recall at ATTD Conference Transcript Insulet: The Growth Doesn't Stop Here Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations Insulet Q1 2026 Earnings Preview Healthcare among laggards in Q1; MRNA and DVA lead gainers while HUM drags
NRG Energy press release ( NRG ): Q1 Non-GAAP EPS of $1.48 misses by $0.25 . Revenue of $10.26B (+19.4% Y/Y) beats by $1.62B . 2026 (In millions, except per share amounts) Guidance Adjusted Net Income $1,685 - $2,115 Adjusted EPS $7.90 - $9.90 Adjusted EBITDA $5,325 - $5,825 FCFbG $2,800 - $3,300 Click to enlarge More on NRG Energy NRG Energy: Too Cheap Into Q1 Earnings, But There's A Technical Ri...
NRG Energy press release ( NRG ): Q1 Non-GAAP EPS of $1.48 misses by $0.25 . Revenue of $10.26B (+19.4% Y/Y) beats by $1.62B . 2026 (In millions, except per share amounts) Guidance Adjusted Net Income $1,685 - $2,115 Adjusted EPS $7.90 - $9.90 Adjusted EBITDA $5,325 - $5,825 FCFbG $2,800 - $3,300 Click to enlarge More on NRG Energy NRG Energy: Too Cheap Into Q1 Earnings, But There's A Technical Risk (Upgrade) NRG Energy, Inc. (NRG) Q4 2025 Earnings Call Transcript NRG Energy, Inc. 2025 Q4 - Results - Earnings Call Presentation NRG Energy Q1 2026 Earnings Preview ClearBridge Select Strategy repositions portfolio with new entries and exits
For years, the two hottest things on Wall Street have been the rise of artificial intelligence (AI) and Nvidia . However, the tide has begun to shift, and Google's parent, Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) , now finds itself in the spotlight. Following the release of its first-quarter operating results last week, Alphabet is roughly $150 billion in market cap away from becoming the most valu...
For years, the two hottest things on Wall Street have been the rise of artificial intelligence (AI) and Nvidia . However, the tide has begun to shift, and Google's parent, Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) , now finds itself in the spotlight. Following the release of its first-quarter operating results last week, Alphabet is roughly $150 billion in market cap away from becoming the most valuable public company. While AI has played an important role in lifting Alphabet's long-term growth prospects, there's another catalyst that's arguably been even more foundational to its 1,000% run-up (including dividends) over the trailing decade. Image source: Getty Images. Continue reading
BioCryst Pharmaceuticals press release ( BCRX ): Q1 GAAP EPS of -$2.98 misses by $3.03 . Revenue of $156.4M (+7.5% Y/Y) beats by $5.28M . Financial Outlook for 2026 The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 millio...
BioCryst Pharmaceuticals press release ( BCRX ): Q1 GAAP EPS of -$2.98 misses by $3.03 . Revenue of $156.4M (+7.5% Y/Y) beats by $5.28M . Financial Outlook for 2026 The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 million and $660 million. The company also maintained its expectation for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to be between $450 million and $470 million. Item As of May 6, 2026 As of February 26, 2026 ORLADEYO revenue Unchanged $625 million to $645 million Total revenue Unchanged $635 million to $660 million Non-GAAP operating expense Unchanged $450 million to $470 million Click to enlarge More on BioCryst Pharmaceuticals BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation BioCryst Pharmaceuticals Q1 2026 Earnings Preview BioCryst gains amid takeover speculation
(RTTNews) - Major stock markets in Asia surged on Wednesday tracking the strong gains in Wall Street, attributed to AI-momentum and U.S.-Iran peace deal hopes. Equity markets in Japan were closed for a holiday.
(RTTNews) - Major stock markets in Asia surged on Wednesday tracking the strong gains in Wall Street, attributed to AI-momentum and U.S.-Iran peace deal hopes. Equity markets in Japan were closed for a holiday.
Dragon Claws/iStock via Getty Images When I last covered Enterprise Products Partners ( EPD ), a big part of the thesis was that it was rapidly approaching a cash flow inflection point where it would be pivoting from investing aggressively in growth projects to seeing its free cash flow soar, its leverage plummet, and its ability to return capital to unit holders increase substantially. Since then...
Dragon Claws/iStock via Getty Images When I last covered Enterprise Products Partners ( EPD ), a big part of the thesis was that it was rapidly approaching a cash flow inflection point where it would be pivoting from investing aggressively in growth projects to seeing its free cash flow soar, its leverage plummet, and its ability to return capital to unit holders increase substantially. Since then, EPD has reported very strong first-quarter results, with first-quarter EBITDA up by 10% year-over-year , and management indicating that the coming quarters may end up being even better. This article will take a fresh look at EPD's business model as well as valuation to share my updated thoughts on it and on whether or not I think it's a buy right now. EPD's Formidable Positioning EPD has a lot going for it even before the recent macro developments pertaining to the Strait of Hormuz. For example, it has one of the largest and most integrated midstream networks in North America, including NGL pipelines, fractionation, natural gas gathering and processing infrastructure, crude oil pipelines, and marine export terminals. Additionally, it controls the whole value chain from wellhead to water as it takes in gas and liquids from producers and then outputs finished products for export. Moreover, it generates largely fee-based earnings as its gross operating margin runs around 74–82% for fee-based earnings, which means that its cash flows are not significantly swung one way or another during periods of commodity price volatility. Finally, about 90% of its long-term contracts have inflation escalators on them, which also makes it a solid inflation-resistant investment. EPD also has a phenomenal balance sheet, as it has the only A-minus credit rating in the entire midstream sector. On top of that, it delivered record operational performance in Q1, with: Natural gas processing volumes are up 7% year over year NGL fractionation volumes up 16% year over year Marine terminal loading vol...
Cyngn (NASDAQ: CYN) will announce its first quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 13, 2026, after the close of market.
Cyngn (NASDAQ: CYN) will announce its first quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 13, 2026, after the close of market.
InMode press release ( INMD ): Non-GAAP EPS of $0.25 misses by $0.05 . Revenue of $82M (+5.3% Y/Y) beats by $2.14M . Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025. ● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million. ● Total cash position of $537.2 million as of March 31, 2026, including c...
InMode press release ( INMD ): Non-GAAP EPS of $0.25 misses by $0.05 . Revenue of $82M (+5.3% Y/Y) beats by $2.14M . Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025. ● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million. ● Total cash position of $537.2 million as of March 31, 2026, including cash and cash equivalents, marketable securities and short-term bank deposits. ● As of March 31, 2026, we completed the repurchase of 2.55 million ordinary shares pursuant to our share repurchase program, returning $34.8 million of capital to shareholders ($3.6 million of which was paid during the second quarter of 2026). ● Announced CFO transition; Yair Malca steps down and will support an orderly transition as a consultant. More on InMode InMode: The Beauty Of A Value Trap InMode Ltd. (INMD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript InMode: Some Green Shoots Appearing, But The Market Hasn't Noticed InMode Q1 2026 Earnings Preview InMode sets new share repurchase program